EICHOR
● Completed
Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
Condition: Invasive Ductal Breast Carcinoma · Sponsor: Fondazione Michelangelo
About this study
This study that aims to evaluate the addition of MPDL3280A (atezolizumab) to carboplatin and nab-paclitaxel in patients with early high-risk and locally advanced triple negative breast cancer. compared to the control arm of carboplatin and abraxane. Half of participants will receive MPDL3280A in combination with carboplatin and abraxane, while the other half will receive only carboplatin and abraxane.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (41)
| Brustgesundheitzentrum Tirol, Univ. Frauenklinik Innsbruck | Innsbruck, Austria | — |
| Universitätsklinik für Innere Medizin III, mit Hämatologie, internistischer Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum | Salzburg, Austria | — |
| Klinikum Augsburg International Patient Service | Augsburg, Germany | — |
| Frauenarzt-Zentrum-Zehlendorf | Berlin, Germany | — |
| Augusta-Kranken-Anstalt gGmbH Klinik für Hämatologie, Onkologie & Palliativmedizin | Bochum, Germany | — |
| Uniklinik Köln Klinik und Poliklinic für Frauenheilkunde und Geburtshilfe Brestzentrum | Cologne, Germany | — |
| Brustzentrum St. Elisabeth-Krankenhaus | Cologne, Germany | — |
| Bethanien-Krankenhaus Onkologisches Zentrum | Frankfurt, Germany | — |
| Markus Krankenhaus Klinik für Gynäkologie und Geburtshilfe | Frankfurt, Germany | — |
| Gynäkologisch-Onkologische Praxis | Hanover, Germany | — |
| NCT Nationales Centrum für Tumorerkrankungen | Heidelberg, Germany | — |
| Interdisciplinary Oncology Center (IOZ) | München, Germany | — |
+ 29 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02620280